All In Biotech

Drug Trial Radar · NCT07288333

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Feb 16, 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Conditions

  • Schizophrenia

Interventions

  • NBI-1117570Drug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 35Time frame: Day 35

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Kazanlak, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Pazardzhik, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Targovishte, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Târgu Mureş, Romania · Recruiting

  • Neurocrine Clinical Site

    London, United Kingdom · Recruiting

  • Neurocrine Clinical Site

    Oxford, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.